AI offers significant future opportunities in prostate cancer care by enhancing diagnostic accuracy and consistency in imaging interpretation, such as mpMRI and PSMA-PET/CT, and supporting risk stratification and personalized treatment recommendations. The gene discussed is FOLH1; the disease is prostate carcinoma.